Olema Pharmaceuticals(NASDAQ) OLMA

Olema develops medicines for women with breast cancer. Its main drug aims to block cancer growth by targeting hormone receptors. These treatments help patients whose cancers resist current therapies.

What’s in the Medicine Cabinet?

• Palazestrant (OP-1250): Oral drug in late-stage trials for hormone-driven breast cancer; no revenue yet.
• OP-3136: Early-stage oral therapy for breast and other solid tumor cancers; not yet commercialized.
• Combination Therapies: Palazestrant tested with other cancer drugs to improve treatment options.
• Research Collaborations: Works with large drugmakers to supply medicines for clinical trials.
• Licensing Agreements: Holds exclusive rights to develop KAT6 inhibitors for cancer treatment.

Growth Spurts and Strategic Moves

• Launched pivotal Phase 3 trials for palazestrant in 2025.
• Formed clinical trial partnerships with Novartis and Pfizer in 2024–2025.
• Advanced OP-3136 into Phase 1 trials after FDA clearance in 2025.
• Out-licensed a non-core research program to Black Shadow Therapeutics in 2024.
• Raised over $440 million through public and private offerings in 2024–2025.

Why Olema Stands Out (Without the Lab Coat)

Olema focuses on new hormone therapies for breast cancer, aiming to address gaps left by older drugs. Its oral medicines target cancer cells more completely than some existing treatments. Strategic partnerships and a growing patent portfolio support its research-driven approach.

Five Things You Need to Know

• No product revenue reported for 2023–2025; all revenue lines are $0.
• Net loss was $-46 million in Q3 2025, down 21.9% from Q3 2024.
• Cash and investments reached $839 million in Q3 2025, up 22.8% year-over-year.
• Operating expenses rose to $178.7 million in 2025, up 25.6% from 2024.

Bottom Line

Olema remains a research-focused company with no product sales to date. Its future depends on advancing new cancer therapies through clinical trials and regulatory review.